葡萄糖酸盐及其水解衍生物:具有抗癌潜力的有希望的植物化学物质
Nataša Joković1, Strahinja Pešić1, Jelena Vitorović1
1Department of Biology and Ecology, Faculty of Science and Mathematics, University of Niš, Niš, Serbia.
Phytotherapy research : PTR
|December 27, 2024
概括
葡萄糖酸盐 (GSL) 和它们的衍生物显示出作为抗癌剂的前景. 这些化合物在棕植物中发现,对各种癌症具有强大的作用,具有良好的生物可用性和低毒性.
科学领域:
- 植物化学 植物化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 植物化学物质,特别是葡萄糖酸盐 (GSL),正作为抗癌剂获得越来越多的关注.
- GSLs是来自Brassicales植物的含硫化合物,通过myrosinase酶产生活性异硫酸盐 (ITC) 和醇.
研究的目的:
- 审查GLS及其衍生物的抗癌潜力.
- 探索它们的作用机制和在各种癌症中的治疗应用.
主要方法:
- 对GLS及其衍生物的临床前和临床研究的文献综述.
- 对它们的抗癌性质,生物可用性,毒性和机制的分析.
主要成果:
- 像硫福拉 (SFN) 和乙烯异硫酸 (PEITC) 这样的特定化合物在乳腺,前列腺,肺部和其他癌症的动物模型中显示出强大的抗癌作用.
- 临床研究证实了SFN和PEITC的化学预防作用,包括致癌物质排毒.
- GSL衍生品显示出良好的生物可用性,低毒性和最小的不良影响.
结论:
- GSL及其衍生物具有作为抗癌化学预防和治疗剂的巨大潜力.
- 需要进一步的临床研究来优化它们在癌症治疗策略中的使用.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K
Phase II Reactions: Glucuronidation
273
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
273
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K


